University of California San Francisco

Robert S. Warren, MD

Robert Warren headshot
Robert S. Warren, MD

Professor of Surgery
Division of Surgical Oncology
Warren Lab in Surgical Oncology

Address

1600 Divisadero, #B606
San Francisco, CA 94115
United States

Email: [email protected]
Phone: 415-353-9297
Fax: 415-353-9695

Biography

Robert S. Warren, M.D. is a Professor of Surgery and a specialist in gastrointestinal and liver cancer. He earned a medical degree at the University of Minnesota, where he completed a general surgery residency. After completing an oncology research fellowship at Memorial Sloan-Kettering Cancer Center in New York, he was an associate physician at Rockefeller University in New York. A board-certified surgeon, Dr. Warren joined UCSF Medical Center in 1988. Highly respected by his peers, Dr. Warren was named to the list of U.S. News "America's Top Doctors," a distinction reserved for the top 1% of physicians in the nation for a given specialty. His research focuses on the biology of colorectal cancer and how it spreads.

Dr. Warren is involved in clinical and laboratory research, which has centered on the biology of colorectal cancer metastasis that includes Vascular Endothelial Growth Factor (VEGF), Insulin-Like Growth Factors and Their Binding Proteins AS Modulators of Growth of Colorectal Cancer Metastases and Cytogenetics of Colorectal Cancer Metastasis. The laboratory work focuses on two areas: 1) autocrine growth factors and angiogenesis in colorectal cancer 2) molecular features which predict clinical outcome in primary and metastatic colorectal cancer.

Education

Institution Degree Dept or School End Date
University of Minnesota M.D. School of Medicine 1980

Board Certifications

  • American Board of Surgery, 1989

Program Affiliations

  • Surgical Oncology Program
  • Surgical Oncology Laboratory
  • UCSF Helen Diller Family Comprehensive Cancer Center
  • UCSF Department of Surgery

Grants and Funding

  • General Clinical Research Center | NIH | 1974-12-01 - 2009-03-31 | Role: Co-Investigator
  • MOLECULAR MARKERS OF PROGNOSIS IN COLON CANCER | NIH | 2000-03-03 - 2006-02-28 | Role: Principal Investigator
  • ROLE OF CYTOKINES IN CANCER PATIENTS UNDERGOING SURGERY | NIH | 1993-07-01 - 1999-06-30 | Role: Principal Investigator

Research Narrative

  • Biology of colorectal cancer metastasis
  • Molecular features which predict clinical outcome in primary and metastatic colorectal cancer
  • Autocrine growth factors and angiogenesis in colorectal cancer
  • Vascular Endothelial Growth Factor (VEGF) Hypoxia and Colon Cancer
  • Insulin-Like Growth Factors and Their Binding Proteins As Modulators of Growth of Colorectal Cancer Metastases
  • Cytogenetics of Colorectal Cancer Metastasis

Publications

MOST RECENT PUBLICATIONS FROM A TOTAL OF 70
  1. Mitogen Inducible Gene-6 Is a Prognostic Marker for Patients with Colorectal Liver Metastases.
    Donner DB, Ruan DT, Toriguchi K, Bergsland EK, Nakakura EK, Lin MH, Antonia RJ, Warren RS| | PubMed
  2. A Patient-derived Xenograft Model of Pancreatic Neuroendocrine Tumors Identifies Sapanisertib as a Possible New Treatment for Everolimus-resistant Tumors.
    Chamberlain CE, German MS, Yang K, Wang J, VanBrocklin H, Regan M, Shokat KM, Ducker GS, Kim GE, Hann B, Donner DB, Warren RS, Venook AP, Bergsland EK, Lee D, Wang Y, Nakakura EK| | PubMed
  3. Sampling strategies to capture single-cell heterogeneity.
    Rajaram S, Heinrich LE, Gordan JD, Avva J, Bonness KM, Witkiewicz AK, Malter JS, Atreya CE, Warren RS, Wu LF, Altschuler SJ| | PubMed
  4. Safety, tumor trafficking and immunogenicity of chimeric antigen receptor (CAR)-T cells specific for TAG-72 in colorectal cancer.
    Hege KM, Bergsland EK, Fisher GA, Nemunaitis JJ, Warren RS, McArthur JG, Lin AA, Schlom J, June CH, Sherwin SA| | PubMed
  5. Reply to L. Casadaban et al.
    Niedzwiecki D, Frankel WL, Venook AP, Ye X, Friedman PN, Goldberg RM, Mayer RJ, Colacchio TA, Mulligan JM, Davison TS, O'Brien E, Kerr P, Johnston PG, Kennedy RD, Harkin DP, Schilsky RL, Bertagnolli MM, Warren RS, Innocenti F| | PubMed
  6. A Study of Thymidylate Synthase Expression as a Biomarker for Resectable Colon Cancer: Alliance (Cancer and Leukemia Group B) 9581 and 89803.
    Niedzwiecki D, Hasson RM, Lenz HJ, Ye C, Redston M, Ogino S, Fuchs CS, Compton CC, Mayer RJ, Goldberg RM, Colacchio TA, Saltz LB, Warren RS, Bertagnolli MM| | PubMed
  7. Association Between Results of a Gene Expression Signature Assay and Recurrence-Free Interval in Patients With Stage II Colon Cancer in Cancer and Leukemia Group B 9581 (Alliance).
    Niedzwiecki D, Frankel WL, Venook AP, Ye X, Friedman PN, Goldberg RM, Mayer RJ, Colacchio TA, Mulligan JM, Davison TS, O'Brien E, Kerr P, Johnston PG, Kennedy RD, Harkin DP, Schilsky RL, Bertagnolli MM, Warren RS, Innocenti F| | PubMed
  8. Unexpected insights for anti-EGFR cancer therapy.
    Depeille P, Warren RS, Roose JP| | PubMed
  9. RasGRP1 opposes proliferative EGFR-SOS1-Ras signals and restricts intestinal epithelial cell growth.
    Depeille P, Henricks LM, van de Ven RA, Lemmens E, Wang CY, Matli M, Werb Z, Haigis KM, Donner D, Warren R, Roose JP| | PubMed
  10. CpG island methylator phenotype is associated with response to adjuvant irinotecan-based therapy for stage III colon cancer.
    Shiovitz S, Bertagnolli MM, Renfro LA, Nam E, Foster NR, Dzieciatkowski S, Luo Y, Lao VV, Monnat RJ, Emond MJ, Maizels N, Niedzwiecki D, Goldberg RM, Saltz LB, Venook A, Warren RS, Grady WM, Alliance for Clinical Trials in Oncology| | PubMed
70
View all 70 Publications
MOST RECENT PUBLICATIONS FROM A TOTAL OF 70
  1. Metastatic colorectal adenocarcinoma tumor purity assessment from whole exome sequencing data.
    Tbeileh N, Timmerman L, Mattis AN, Toriguchi K, Kasai Y, Corvera C, Nakakura E, Hirose K, Donner DB, Warren RS, Karelehto E| | PubMed
  2. STAT3 regulates inflammatory cytokine production downstream of TNFR1 by inducing expression of TNFAIP3/A20.
    Antonia RJ, Karelehto E, Toriguchi K, Matli M, Warren RS, Pfeffer LM, Donner DB| | PubMed
  3. Synchronous Versus Metachronous Colorectal Liver Metastasis Yields Similar Survival in Modern Era.
    Wisneski AD, Jin C, Huang CY, Warren R, Hirose K, Nakakura EK, Corvera CU| | PubMed
  4. RBMS1 Suppresses Colon Cancer Metastasis through Targeted Stabilization of Its mRNA Regulon.
    Yu J, Navickas A, Asgharian H, Culbertson B, Fish L, Garcia K, Olegario JP, Dermit M, Dodel M, Hänisch B, Luo Y, Weinberg EM, Dienstmann R, Warren RS, Mardakheh FK, Goodarzi H| | PubMed
  5. A novel stratification of mesenteric mass involvement as a predictor of challenging mesenteric lymph node dissection by minimally invasive approach for ileal neuroendocrine tumors.
    Kasai Y, Mahuron K, Hirose K, Corvera CU, Kim GE, Hope TA, Shih BE, Warren RS, Bergsland EK, Nakakura EK| | PubMed
  6. Residual tumor volume discriminates prognosis after surgery for neuroendocrine liver metastasis.
    Kasai Y, Hirose K, Corvera CU, Kim GE, Hope TA, Shih BE, Harun N, Kim MO, Warren RS, Bergsland EK, Nakakura EK| | PubMed
  7. Prognostic impact of a large mesenteric mass >2 cm in ileal neuroendocrine tumors.
    Kasai Y, Mahuron K, Hirose K, Corvera CU, Kim GE, Hope TA, Shih BE, Warren RS, Bergsland EK, Nakakura EK| | PubMed
  8. Relative contribution of clinicopathological variables, genomic markers, transcriptomic subtyping and microenvironment features for outcome prediction in stage II/III colorectal cancer.
    Dienstmann R, Villacampa G, Sveen A, Mason MJ, Niedzwiecki D, Nesbakken A, Moreno V, Warren RS, Lothe RA, Guinney J| | PubMed
  9. High thymidylate synthase gene expression predicts poor outcome after resection of hepatocellular carcinoma.
    Donner DB, Nakakura EK, Venook AP, Lenz HJ, Zhang W, Hwang J, Bergsland EK, Lin MH, Toriguchi K, Antonia RJ, Warren RS| | PubMed
  10. RasGRP1 is a potential biomarker to stratify anti-EGFR therapy response in colorectal cancer.
    Gbenedio OM, Bonnans C, Grun D, Wang CY, Hatch AJ, Mahoney MR, Barras D, Matli M, Miao Y, Garcia KC, Tejpar S, Delorenzi M, Venook AP, Nixon AB, Warren RS, Roose JP, Depeille P| | PubMed
  11. Mitogen Inducible Gene-6 Is a Prognostic Marker for Patients with Colorectal Liver Metastases.
    Donner DB, Ruan DT, Toriguchi K, Bergsland EK, Nakakura EK, Lin MH, Antonia RJ, Warren RS| | PubMed
  12. A Patient-derived Xenograft Model of Pancreatic Neuroendocrine Tumors Identifies Sapanisertib as a Possible New Treatment for Everolimus-resistant Tumors.
    Chamberlain CE, German MS, Yang K, Wang J, VanBrocklin H, Regan M, Shokat KM, Ducker GS, Kim GE, Hann B, Donner DB, Warren RS, Venook AP, Bergsland EK, Lee D, Wang Y, Nakakura EK| | PubMed
  13. Sampling strategies to capture single-cell heterogeneity.
    Rajaram S, Heinrich LE, Gordan JD, Avva J, Bonness KM, Witkiewicz AK, Malter JS, Atreya CE, Warren RS, Wu LF, Altschuler SJ| | PubMed
  14. Safety, tumor trafficking and immunogenicity of chimeric antigen receptor (CAR)-T cells specific for TAG-72 in colorectal cancer.
    Hege KM, Bergsland EK, Fisher GA, Nemunaitis JJ, Warren RS, McArthur JG, Lin AA, Schlom J, June CH, Sherwin SA| | PubMed
  15. Reply to L. Casadaban et al.
    Niedzwiecki D, Frankel WL, Venook AP, Ye X, Friedman PN, Goldberg RM, Mayer RJ, Colacchio TA, Mulligan JM, Davison TS, O'Brien E, Kerr P, Johnston PG, Kennedy RD, Harkin DP, Schilsky RL, Bertagnolli MM, Warren RS, Innocenti F| | PubMed
  16. A Study of Thymidylate Synthase Expression as a Biomarker for Resectable Colon Cancer: Alliance (Cancer and Leukemia Group B) 9581 and 89803.
    Niedzwiecki D, Hasson RM, Lenz HJ, Ye C, Redston M, Ogino S, Fuchs CS, Compton CC, Mayer RJ, Goldberg RM, Colacchio TA, Saltz LB, Warren RS, Bertagnolli MM| | PubMed
  17. Association Between Results of a Gene Expression Signature Assay and Recurrence-Free Interval in Patients With Stage II Colon Cancer in Cancer and Leukemia Group B 9581 (Alliance).
    Niedzwiecki D, Frankel WL, Venook AP, Ye X, Friedman PN, Goldberg RM, Mayer RJ, Colacchio TA, Mulligan JM, Davison TS, O'Brien E, Kerr P, Johnston PG, Kennedy RD, Harkin DP, Schilsky RL, Bertagnolli MM, Warren RS, Innocenti F| | PubMed
  18. Unexpected insights for anti-EGFR cancer therapy.
    Depeille P, Warren RS, Roose JP| | PubMed
  19. RasGRP1 opposes proliferative EGFR-SOS1-Ras signals and restricts intestinal epithelial cell growth.
    Depeille P, Henricks LM, van de Ven RA, Lemmens E, Wang CY, Matli M, Werb Z, Haigis KM, Donner D, Warren R, Roose JP| | PubMed
  20. CpG island methylator phenotype is associated with response to adjuvant irinotecan-based therapy for stage III colon cancer.
    Shiovitz S, Bertagnolli MM, Renfro LA, Nam E, Foster NR, Dzieciatkowski S, Luo Y, Lao VV, Monnat RJ, Emond MJ, Maizels N, Niedzwiecki D, Goldberg RM, Saltz LB, Venook A, Warren RS, Grady WM, Alliance for Clinical Trials in Oncology| | PubMed
  21. Prognostic impact of deficient DNA mismatch repair in patients with stage III colon cancer from a randomized trial of FOLFOX-based adjuvant chemotherapy.
    Sinicrope FA, Mahoney MR, Smyrk TC, Thibodeau SN, Warren RS, Bertagnolli MM, Nelson GD, Goldberg RM, Sargent DJ, Alberts SR| | PubMed
  22. Wild type p53 transcriptionally represses the SALL2 transcription factor under genotoxic stress.
    Farkas C, Martins CP, Escobar D, Hepp MI, Castro AF, Evan G, Gutiérrez JL, Warren R, Donner DB, Pincheira R| | PubMed
  23. Association of TP53 mutational status and gender with survival after adjuvant treatment for stage III colon cancer: results of CALGB 89803.
    Warren RS, Atreya CE, Niedzwiecki D, Weinberg VK, Donner DB, Mayer RJ, Goldberg RM, Compton CC, Zuraek MB, Ye C, Saltz LB, Bertagnolli MM| | PubMed
  24. PTEN expression is consistent in colorectal cancer primaries and metastases and associates with patient survival.
    Atreya CE, Sangale Z, Xu N, Matli MR, Tikishvili E, Welbourn W, Stone S, Shokat KM, Warren RS| | PubMed
  25. Incomplete inhibition of phosphorylation of 4E-BP1 as a mechanism of primary resistance to ATP-competitive mTOR inhibitors.
    Ducker GS, Atreya CE, Simko JP, Hom YK, Matli MR, Benes CH, Hann B, Nakakura EK, Bergsland EK, Donner DB, Settleman J, Shokat KM, Warren RS| | PubMed
  26. Biologic determinants of tumor recurrence in stage II colon cancer: validation study of the 12-gene recurrence score in cancer and leukemia group B (CALGB) 9581.
    Venook AP, Niedzwiecki D, Lopatin M, Ye X, Lee M, Friedman PN, Frankel W, Clark-Langone K, Millward C, Shak S, Goldberg RM, Mahmoud NN, Warren RS, Schilsky RL, Bertagnolli MM| | PubMed
  27. Imaging a functional tumorigenic biomarker in the transformed epithelium.
    LeBeau AM, Lee M, Murphy ST, Hann BC, Warren RS, Delos Santos R, Kurhanewicz J, Hanash SM, VanBrocklin HF, Craik CS| | PubMed
  28. Lymph node sampling rates and predictors of nodal metastasis in pancreatic neuroendocrine tumor resections: the UCSF experience with 149 patients.
    Parekh JR, Wang SC, Bergsland EK, Venook AP, Warren RS, Kim GE, Nakakura EK| | PubMed
  29. Combination of ATP-competitive mammalian target of rapamycin inhibitors with standard chemotherapy for colorectal cancer.
    Atreya CE, Ducker GS, Feldman ME, Bergsland EK, Warren RS, Shokat KM| | PubMed
  30. Is there currently an established role for the use of predictive or prognostic molecular markers in the management of colorectal cancer? A point/counterpoint.
    Venook AP, Bendell JC, Warren RS| | PubMed
  31. Complete and safe resection of challenging retroperitoneal tumors: anticipation of multi-organ and major vascular resection and use of adjunct procedures.
    Tseng WW, Wang SC, Eichler CM, Warren RS, Nakakura EK| | PubMed
  32. Documenting the natural history of patients with resected stage II adenocarcinoma of the colon after random assignment to adjuvant treatment with edrecolomab or observation: results from CALGB 9581.
    Niedzwiecki D, Bertagnolli MM, Warren RS, Compton CC, Kemeny NE, Benson AB, Eckhardt SG, Alberts S, Porjosh GN, Kerr DJ, Fields A, Rougier P, Pipas JM, Schwartz JH, Atkins J, O'Rourke M, Perry MC, Goldberg RM, Mayer RJ, Colacchio TA| | PubMed
  33. Microsatellite instability and loss of heterozygosity at chromosomal location 18q: prospective evaluation of biomarkers for stages II and III colon cancer--a study of CALGB 9581 and 89803.
    Bertagnolli MM, Redston M, Compton CC, Niedzwiecki D, Mayer RJ, Goldberg RM, Colacchio TA, Saltz LB, Warren RS| | PubMed
  34. Pancreatic adenocarcinoma.
    Tempero MA, Arnoletti JP, Behrman S, Ben-Josef E, Benson AB, Berlin JD, Cameron JL, Casper ES, Cohen SJ, Duff M, Ellenhorn JD, Hawkins WG, Hoffman JP, Kuvshinoff BW, Malafa MP, Muscarella P, Nakakura EK, Sasson AR, Thayer SP, Tyler DS, Warren RS, Whiting S, Willett C, Wolff RA, NCCN Pancreatic Adenocarcinoma| | PubMed
  35. Lack of NKX2.2 expression in bronchopulmonary typical carcinoid tumors: implications for patients with neuroendocrine tumor metastases and unknown primary site.
    Wang YC, Iezza G, Zuraek MB, Jablons DM, Theodore PR, Bergsland EK, Donner DB, Warren RS, Nakakura EK| | PubMed
  36. Identification of unknown primary tumors in patients with neuroendocrine liver metastases.
    Wang SC, Parekh JR, Zuraek MB, Venook AP, Bergsland EK, Warren RS, Nakakura EK| | PubMed
  37. The ETS oncogene family transcription factor FEV identifies serotonin-producing cells in normal and neoplastic small intestine.
    Wang YC, Zuraek MB, Kosaka Y, Ota Y, German MS, Deneris ES, Bergsland EK, Donner DB, Warren RS, Nakakura EK| | PubMed
  38. p27Kip1 in stage III colon cancer: implications for outcome following adjuvant chemotherapy in cancer and leukemia group B protocol 89803.
    Bertagnolli MM, Warren RS, Niedzwiecki D, Mueller E, Compton CC, Redston M, Hall M, Hahn HP, Jewell SD, Mayer RJ, Goldberg RM, Saltz LB, Loda M| | PubMed
  39. Microsatellite instability predicts improved response to adjuvant therapy with irinotecan, fluorouracil, and leucovorin in stage III colon cancer: Cancer and Leukemia Group B Protocol 89803.
    Bertagnolli MM, Niedzwiecki D, Compton CC, Hahn HP, Hall M, Damas B, Jewell SD, Mayer RJ, Goldberg RM, Saltz LB, Warren RS, Redston M| | PubMed
  40. Mitogen-inducible gene-6 expression correlates with survival and is an independent predictor of recurrence in BRAF(V600E) positive papillary thyroid cancers.
    Ruan DT, Warren RS, Moalem J, Chung KW, Griffin AC, Shen W, Duh QY, Nakakura E, Donner DB, Khanafshar E, Weng J, Clark OH, Kebebew E| | PubMed
  41. Homeodomain transcription factor NKX2.2 functions in immature cells to control enteroendocrine differentiation and is expressed in gastrointestinal neuroendocrine tumors.
    Wang YC, Gallego-Arteche E, Iezza G, Yuan X, Matli MR, Choo SP, Zuraek MB, Gogia R, Lynn FC, German MS, Bergsland EK, Donner DB, Warren RS, Nakakura EK| | PubMed
  42. Association of family history with cancer recurrence and survival among patients with stage III colon cancer.
    Chan JA, Meyerhardt JA, Niedzwiecki D, Hollis D, Saltz LB, Mayer RJ, Thomas J, Schaefer P, Whittom R, Hantel A, Goldberg RM, Warren RS, Bertagnolli M, Fuchs CS| | PubMed
  43. Compound muscle action potentials and spontaneous electromyography can be used to identify and protect the femoral nerve during resection of large retroperitoneal tumors.
    Guo L, Clark JP, Warren RS, Nakakura EK| | PubMed
  44. Prognostic importance of superior diaphragmatic adenopathy at computed tomography in patients with resectable hepatic metastases from colorectal carcinoma.
    Aslam R, Coakley FV, Williams G, Yeh BM, Joe BN, Zuraek MB, Warren RS| | PubMed
  45. Introduction.
    Warren RS, Nakakura EK| | PubMed
  46. Palliative care for patients with advanced pancreatic and biliary cancers.
    Nakakura EK, Warren RS| | PubMed
  47. Nutlin3 blocks vascular endothelial growth factor induction by preventing the interaction between hypoxia inducible factor 1alpha and Hdm2.
    LaRusch GA, Jackson MW, Dunbar JD, Warren RS, Donner DB, Mayo LD| | PubMed
  48. Pancreatoblastoma in an adult: case report and review of the literature.
    Rajpal S, Warren RS, Alexander M, Yeh BM, Grenert JP, Hintzen S, Ljung BM, Bergsland EK| | PubMed
  49. Hepatic arterial infusion versus systemic therapy for hepatic metastases from colorectal cancer: a randomized trial of efficacy, quality of life, and molecular markers (CALGB 9481).
    Kemeny NE, Niedzwiecki D, Hollis DR, Lenz HJ, Warren RS, Naughton MJ, Weeks JC, Sigurdson ER, Herndon JE, Zhang C, Mayer RJ| | PubMed
  50. Pancreatic adenocarcinoma: Clinical Practice Guidelines in Oncology.
    Tempero MA, Behrman S, Ben-Josef E, Benson AB, Cameron JL, Casper ES, Hoffman JP, Karl RC, Kim P, Koh WJ, Kuvshinoff BW, Melvin WS, Muscarella P, Sasson AR, Shibata S, Shrieve DC, Talamonti MS, Tyler DS, Vickers SM, Warren RS, Willett C, Wolff RA, National Comprehensive Cancer Network| | PubMed
  51. [Liver metastases from colorectal cancer. Is the practice of surgery based on the best clinical evidence possible?].
    Durán Giménez-Rico H, García-Aguilar J, Warren RS, Iborra P, Guerrero V| | PubMed
  52. Hypoxia-induced radioresistance is independent of hypoxia-inducible factor-1A in vitro.
    Arvold ND, Guha N, Wang D, Matli M, Deen DF, Warren RS, Haas-Kogan DA| | PubMed
  53. Fractional genomic alteration detected by array-based comparative genomic hybridization independently predicts survival after hepatic resection for metastatic colorectal cancer.
    Mehta KR, Nakao K, Zuraek MB, Ruan DT, Bergsland EK, Venook AP, Moore DH, Tokuyasu TA, Jain AN, Warren RS, Terdiman JP, Waldman FM| | PubMed
  54. Liver-directed therapies in colorectal cancer.
    Ruan DT, Warren RS| | PubMed
  55. Palliative techniques for hepatic cancer.
    Ruan DT, Warren RS| | PubMed
  56. Characterization of triacsin C inhibition of short-, medium-, and long-chain fatty acid: CoA ligases of human liver.
    Vessey DA, Kelley M, Warren RS| | PubMed
  57. Aggressive surgery for metastatic liver neuroendocrine tumors.
    Norton JA, Warren RS, Kelly MG, Zuraek MB, Jensen RT| | PubMed
  58. beta-Catenin regulates vascular endothelial growth factor expression in colon cancer.
    Easwaran V, Lee SH, Inge L, Guo L, Goldbeck C, Garrett E, Wiesmann M, Garcia PD, Fuller JH, Chan V, Randazzo F, Gundel R, Warren RS, Escobedo J, Aukerman SL, Taylor RN, Fantl WJ| | PubMed
  59. Distinguishing features of self-limiting adult small-bowel intussusception identified at CT.
    Lvoff N, Breiman RS, Coakley FV, Lu Y, Warren RS| | PubMed
  60. Isolation, sequencing, and expression of a cDNA for the HXM-A form of xenobiotic/medium-chain fatty acid:CoA ligase from human liver mitochondria.
    Vessey DA, Lau E, Kelley M, Warren RS| | PubMed
  61. Thorotrast-induced liver neoplasia: a collective review.
    Lipshutz GS, Brennan TV, Warren RS| | PubMed
  62. Detection of hepatic metastases from cancers of the gastrointestinal tract by using noninvasive imaging methods (US, CT, MR imaging, PET): a meta-analysis.
    Kinkel K, Lu Y, Both M, Warren RS, Thoeni RF| | PubMed
  63. Liver-directed viral therapy for cancer p53-targeted adenoviruses and beyond.
    Warren RS, Kirn DH| | PubMed
  64. Expression and endocytosis of VEGF and its receptors in human colonic vascular endothelial cells.
    Wang D, Lehman RE, Donner DB, Matli MR, Warren RS, Welton ML| | PubMed
  65. Quantitative fractionation of alkaline phosphatase isoenzymes according to their thermostability.
    PetitClerc C| | PubMed
  66. Activity and longevity of insect growth regulators against mosquitoes.
    Mulla MS, Darwazeh HA| | PubMed
  67. A double-blind controlled therapeutic trial of lorazepam vs medazepam in psychosomatic conditions in general practice.
    Sim M, Bindman E, Morrison I, Sandilands D| | PubMed
  68. Analyses of rumen fluid from "sudden death", lactic acidotic and healthy cattle fed high concentrate ration.
    Wilson JR, Bartley EE, Anthony HD, Brent BE, Sapienza DA, Chapman TE, Dayton AD, Milleret RJ, Frey RA, Meyer RM| | PubMed
  69. Action of propranolol on mitochondrial functions--effects on energized ion fluxes in the presence of valinomycin.
    Järvisalo J, Saris NE| | PubMed
  70. Digitoxin metabolism by rat liver microsomes.
    Schmoldt A, Benthe HF, Haberland G| | PubMed